vs
阿普塔集团（ATR）与瑞思迈（RMD）财务数据对比。点击上方公司名可切换其他公司
瑞思迈的季度营收约是阿普塔集团的1.5倍（$1.4B vs $962.7M），瑞思迈净利率更高（27.6% vs 7.7%，领先19.9%），阿普塔集团同比增速更快（13.5% vs 11.0%），瑞思迈自由现金流更多（$311.2M vs $96.9M），过去两年瑞思迈的营收复合增速更高（9.0% vs 2.6%）
阿普塔集团（AptarGroup, Inc.）是总部位于美国的全球性制造企业，主营消费品分配包装产品及药物给药装置的研发与生产，目前在全球18个国家设有生产运营基地，服务医药、快消等多领域客户。
瑞思迈是一家起源于澳大利亚、总部位于美国加利福尼亚州圣迭戈的医疗设备企业，主打可接入云端的呼吸类医疗设备，用于治疗睡眠呼吸暂停、慢性阻塞性肺病等呼吸道疾病，新冠疫情期间曾大量生产呼吸机等设备助力患者救治。
ATR vs RMD — 直观对比
营收规模更大
RMD
是对方的1.5倍
$962.7M
营收增速更快
ATR
高出2.5%
11.0%
净利率更高
RMD
高出19.9%
7.7%
自由现金流更多
RMD
多$214.3M
$96.9M
两年增速更快
RMD
近两年复合增速
2.6%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $962.7M | $1.4B |
| 净利润 | $74.3M | $392.6M |
| 毛利率 | — | 61.8% |
| 营业利润率 | 11.0% | 34.6% |
| 净利率 | 7.7% | 27.6% |
| 营收同比 | 13.5% | 11.0% |
| 净利润同比 | -26.4% | 13.9% |
| 每股收益（稀释后） | $1.13 | $2.68 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ATRRMD
| Q4 25 | $962.7M | $1.4B | ||
| Q3 25 | $961.1M | $1.3B | ||
| Q2 25 | $966.0M | $1.3B | ||
| Q1 25 | $887.3M | $1.3B | ||
| Q4 24 | $848.1M | $1.3B | ||
| Q3 24 | $909.3M | $1.2B | ||
| Q2 24 | $910.1M | $1.2B | ||
| Q1 24 | $915.4M | $1.2B |
净利润ATRRMD
| Q4 25 | $74.3M | $392.6M | ||
| Q3 25 | $127.9M | $348.5M | ||
| Q2 25 | $111.7M | $379.7M | ||
| Q1 25 | $78.8M | $365.0M | ||
| Q4 24 | $100.9M | $344.6M | ||
| Q3 24 | $100.0M | $311.4M | ||
| Q2 24 | $90.5M | $292.2M | ||
| Q1 24 | $83.1M | $300.5M |
毛利率ATRRMD
| Q4 25 | — | 61.8% | ||
| Q3 25 | — | 61.5% | ||
| Q2 25 | — | 60.8% | ||
| Q1 25 | — | 59.3% | ||
| Q4 24 | — | 58.6% | ||
| Q3 24 | — | 58.6% | ||
| Q2 24 | — | 58.5% | ||
| Q1 24 | — | 57.9% |
营业利润率ATRRMD
| Q4 25 | 11.0% | 34.6% | ||
| Q3 25 | 14.2% | 33.4% | ||
| Q2 25 | 14.9% | 33.7% | ||
| Q1 25 | 12.8% | 33.0% | ||
| Q4 24 | 14.2% | 32.5% | ||
| Q3 24 | 15.2% | 31.6% | ||
| Q2 24 | 13.8% | 31.2% | ||
| Q1 24 | 12.2% | 31.3% |
净利率ATRRMD
| Q4 25 | 7.7% | 27.6% | ||
| Q3 25 | 13.3% | 26.1% | ||
| Q2 25 | 11.6% | 28.2% | ||
| Q1 25 | 8.9% | 28.3% | ||
| Q4 24 | 11.9% | 26.9% | ||
| Q3 24 | 11.0% | 25.4% | ||
| Q2 24 | 9.9% | 23.9% | ||
| Q1 24 | 9.1% | 25.1% |
每股收益（稀释后）ATRRMD
| Q4 25 | $1.13 | $2.68 | ||
| Q3 25 | $1.92 | $2.37 | ||
| Q2 25 | $1.67 | $2.58 | ||
| Q1 25 | $1.17 | $2.48 | ||
| Q4 24 | $1.48 | $2.34 | ||
| Q3 24 | $1.48 | $2.11 | ||
| Q2 24 | $1.34 | $1.97 | ||
| Q1 24 | $1.23 | $2.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $409.5M | $1.4B |
| 总债务越低越好 | $1.1B | $403.9M |
| 股东权益账面价值 | $2.7B | $6.3B |
| 总资产 | $5.3B | $8.5B |
| 负债/权益比越低杠杆越低 | 0.43× | 0.06× |
8季度趋势，按日历期对齐
现金及短期投资ATRRMD
| Q4 25 | $409.5M | $1.4B | ||
| Q3 25 | $264.8M | $1.4B | ||
| Q2 25 | $169.8M | $1.2B | ||
| Q1 25 | $136.8M | $932.7M | ||
| Q4 24 | $226.2M | $521.9M | ||
| Q3 24 | $327.9M | $426.4M | ||
| Q2 24 | $223.9M | $238.4M | ||
| Q1 24 | $201.1M | $237.9M |
总债务ATRRMD
| Q4 25 | $1.1B | $403.9M | ||
| Q3 25 | $546.0M | $408.7M | ||
| Q2 25 | $535.1M | $658.4M | ||
| Q1 25 | $561.2M | $663.1M | ||
| Q4 24 | $688.1M | $662.9M | ||
| Q3 24 | $822.7M | $667.6M | ||
| Q2 24 | $681.5M | $697.3M | ||
| Q1 24 | $680.4M | $997.0M |
股东权益ATRRMD
| Q4 25 | $2.7B | $6.3B | ||
| Q3 25 | $2.8B | $6.1B | ||
| Q2 25 | $2.7B | $6.0B | ||
| Q1 25 | $2.5B | $5.5B | ||
| Q4 24 | $2.5B | $5.3B | ||
| Q3 24 | $2.5B | $5.2B | ||
| Q2 24 | $2.4B | $4.9B | ||
| Q1 24 | $2.3B | $4.6B |
总资产ATRRMD
| Q4 25 | $5.3B | $8.5B | ||
| Q3 25 | $5.1B | $8.3B | ||
| Q2 25 | $4.9B | $8.2B | ||
| Q1 25 | $4.5B | $7.6B | ||
| Q4 24 | $4.4B | $7.1B | ||
| Q3 24 | $4.6B | $7.2B | ||
| Q2 24 | $4.5B | $6.9B | ||
| Q1 24 | $4.4B | $6.8B |
负债/权益比ATRRMD
| Q4 25 | 0.43× | 0.06× | ||
| Q3 25 | 0.20× | 0.07× | ||
| Q2 25 | 0.20× | 0.11× | ||
| Q1 25 | 0.22× | 0.12× | ||
| Q4 24 | 0.28× | 0.13× | ||
| Q3 24 | 0.32× | 0.13× | ||
| Q2 24 | 0.28× | 0.14× | ||
| Q1 24 | 0.29× | 0.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $183.7M | $339.7M |
| 自由现金流经营现金流 - 资本支出 | $96.9M | $311.2M |
| 自由现金流率自由现金流/营收 | 10.1% | 21.9% |
| 资本支出强度资本支出/营收 | 9.0% | 2.0% |
| 现金转化率经营现金流/净利润 | 2.47× | 0.87× |
| 过去12个月自由现金流最近4个季度 | $299.6M | $1.8B |
8季度趋势，按日历期对齐
经营现金流ATRRMD
| Q4 25 | $183.7M | $339.7M | ||
| Q3 25 | $177.6M | $457.3M | ||
| Q2 25 | $126.0M | $538.8M | ||
| Q1 25 | $82.7M | $578.7M | ||
| Q4 24 | $178.2M | $308.6M | ||
| Q3 24 | $229.3M | $325.5M | ||
| Q2 24 | $143.6M | $440.1M | ||
| Q1 24 | $92.3M | $402.0M |
自由现金流ATRRMD
| Q4 25 | $96.9M | $311.2M | ||
| Q3 25 | $114.3M | $414.4M | ||
| Q2 25 | $62.5M | $508.2M | ||
| Q1 25 | $25.9M | $557.9M | ||
| Q4 24 | $112.2M | $288.0M | ||
| Q3 24 | $162.7M | $307.7M | ||
| Q2 24 | $75.4M | $415.2M | ||
| Q1 24 | $16.7M | $380.8M |
自由现金流率ATRRMD
| Q4 25 | 10.1% | 21.9% | ||
| Q3 25 | 11.9% | 31.0% | ||
| Q2 25 | 6.5% | 37.7% | ||
| Q1 25 | 2.9% | 43.2% | ||
| Q4 24 | 13.2% | 22.5% | ||
| Q3 24 | 17.9% | 25.1% | ||
| Q2 24 | 8.3% | 33.9% | ||
| Q1 24 | 1.8% | 31.8% |
资本支出强度ATRRMD
| Q4 25 | 9.0% | 2.0% | ||
| Q3 25 | 6.6% | 3.2% | ||
| Q2 25 | 6.6% | 2.3% | ||
| Q1 25 | 6.4% | 1.6% | ||
| Q4 24 | 7.8% | 1.6% | ||
| Q3 24 | 7.3% | 1.5% | ||
| Q2 24 | 7.5% | 2.0% | ||
| Q1 24 | 8.3% | 1.8% |
现金转化率ATRRMD
| Q4 25 | 2.47× | 0.87× | ||
| Q3 25 | 1.39× | 1.31× | ||
| Q2 25 | 1.13× | 1.42× | ||
| Q1 25 | 1.05× | 1.59× | ||
| Q4 24 | 1.77× | 0.90× | ||
| Q3 24 | 2.29× | 1.05× | ||
| Q2 24 | 1.59× | 1.51× | ||
| Q1 24 | 1.11× | 1.34× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ATR
| Pharma Segment | $833.1M | 87% |
| Other | $129.6M | 13% |
RMD
| Sleep And Breathing Health | $1.3B | 88% |
| Residential Care Software | $166.9M | 12% |
